For example, three EZH2 inhibitors, tazemetostat (EPZ-6438), GSK2816126, and CPI-1205, have moved into phase I/phase II clinical trials in patients with non-Hodgkin lymphoma and genetically defined solid tumors [33]. Here, EZH2 is linked to non-Hodgkin lymphoma.